Prognostication of mortality in critically Ill patients with severe infections

Chest

Volumn 148, Issue 3, 2015, Pages 674-682

  Que, Yok Ai ^a   Guessous, Idris ^b,c   Dupuis Lozeron, Elise ^c,d   De Oliveira, Clara Rodrigues Alves ^a   Oliveira, Carolina Ferreira ^a   Graf, Rolf ^e   Seematter, Gérald ^f   Revelly, Jean Pierre ^a   Pagani, Jean Luc ^a   Liaudet, Lucas ^a   Nobre, Vandack ^g   Eggimann, Philippe ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f Hopital Riviera   (Switzerland)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; LITHOSTATHINE; PROCALCITONIN; CALCITONIN; PROTEIN PRECURSOR; REG1A PROTEIN, HUMAN;

ADULT; APACHE; ARTICLE; BRAZIL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; FEMALE; HOSPITAL PATIENT; HUMAN; INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SEPTIC SHOCK; SURVIVAL RATE; SWITZERLAND; VALIDATION STUDY; CLINICAL TRIAL; CRITICAL ILLNESS; EPIDEMIOLOGY; INTENSIVE CARE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SEPSIS; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; BRAZIL; C-REACTIVE PROTEIN; CALCITONIN; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; HOSPITAL MORTALITY; HUMANS; LITHOSTATHINE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEPSIS; SEVERITY OF ILLNESS INDEX; SWITZERLAND;

EID: 84941710673     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0123     Document Type: Article

References (47)

1. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Effi cacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344 ( 10): 699-709.
2. Vincent JL, Sakr Y, Sprung CL, et al; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006; 34 ( 2): 344-353.
3. Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009; 302 ( 21): 2323-2329.
4. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. I ntensive Care Med. 2013; 39 ( 2): 165-228.
5. Calandra T, Glauser MP, Schellekens J, Verhoef J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, doubleblind, randomized trial. J Infect Dis. 1988; 158 ( 2): 312-319.
6. Abraham E, Anzueto A, Gutierrez G, et al; NORASEPT II Study Group. Doubleblind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998; 351 ( 9107): 929-933.
7. Opal S, Laterre PF, Abraham E, et al; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebocontrolled, clinical trial. Crit Care Med. 2004; 32 ( 2): 332-341.
8. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348 ( 2): 138-150.
9. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012; 366 ( 22): 2055-2064.
10. Opal SM, Laterre PF, Francois B, et al; ACCESS Study Group. Eff ect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA. 2013; 309 ( 11): 1154-1162.
11. Bernard GR, Francois B, Mira JP, et al. Evaluating the effi cacy and safety of two doses of the polyclonal anti-tumor necrosis factor-A fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med. 2014; 42 ( 3): 504-511.
12. Vincent JL, Donadello K, Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin. 2011; 27 ( 2): 241-251.
13. Que YA, Virgini V, Lozeron ED, et al. Low C-reactive protein values at admission predict mortality in patients with severe community-acquired pneumoniacaused by Streptococcus pneumoniae that require intensive care management. Infection. 2015; 43 ( 2): 193-199.
14. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007; 7 ( 3): 210-217.
15. Keel M, Härter L, Reding T, et al. Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. Crit Care Med. 2009; 37 ( 5): 1642-1648.
16. Schlapbach LJ, Graf R, Woerner A, et al. Pancreatic stone protein as a novel marker for neonatal sepsis. Intensive Care Med. 2013; 39 ( 4): 754-763.
17. Llewelyn MJ, Berger M, Gregory M, et al. Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Crit Care. 2013; 17 ( 2): R60.
18. Klein HJ, Csordas A, Falk V, et al. Pancreatic stone protein predicts postoperative infection in cardiac surgery patients irrespective of cardiopulmonary bypass or surgical technique. PLoS ONE. 2015; 10 ( 3): e0120276.
19. Boeck L, Graf R, Eggimann P, et al. Pancreatic stone protein: A marker of organ failure and outcome in ventilatorassociated pneumonia. Chest. 2011; 140 ( 4): 925-932.
20. Que YA, Delodder F, Guessous I, et al. Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Crit Care. 2012; 16 ( 4): R114.
21. Gukasjan R, Raptis DA, Schulz HU, Halangk W, Graf R. Pancreatic stone protein predicts outcome in patients with peritonitis in the ICU. Crit Care Med. 2013; 41 ( 4): 1027-1036.
22. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferonalpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990; 161 ( 5): 982-987.
23. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991; 91 ( 1): 23-29.
24. Pierrakos C, Vincent JL. Sepsis biomarkers: A review. Crit Care. 2010; 14 ( 1): R15.
25. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Defi nitions Conference. Crit Care Med. 2003; 31 ( 4): 1250-1256.
26. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC defi nitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16 ( 3): 128-140.
27. Calandra T, Cohen J; International Sepsis Forum Defi nition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on defi nitions of infection in the intensive care unit. Crit Care Med. 2005; 33 ( 7): 1538-1548.
28. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988; 44 ( 3): 837-845.
29. Efron B. How biased is the apparent error rate of a prediction rule? J Am Stat Assoc. 1986; 81 ( 394): 461-470.
30. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifi er performance in R. Bioinformatics. 2005; 21 ( 20): 3940-3941.
31. Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. J R Stat Soc Series B Stat Methodol. 2011; 73 ( 1): 3-36.
32. Robin X, Turck N, Hainard A, et al. pROC: An open-source package for R and S 1 to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12 ( 1): 77.
33. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer; 2009.
34. Bouadma L, Luyt CE, Tubach F, et al; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet. 2010; 375 ( 9713): 463-474.
35. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: A systematic review and meta-analysis. Lancet Infect Dis. 2013; 13 ( 5): 426-435.
36. Vincent JL, Opal SM, Marshall JC. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med. 2010; 38 ( 1): 283-287.
37. Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med. 2009; 37 ( 1): 96-104.
38. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, et al. Risk assessment in sepsis: A new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012; 16 ( 4): R149.
39. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibañez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013; 39 ( 11): 1945-1952.
40. Alan M, Grolimund E, Kutz A, et al; the ProHOSP study group. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: A 6-year prospective follow-up study [published online ahead of print December 19, 2014]. J Intern Med. doi:10. 1111/ joim. 12341.
41. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29 ( 7): 1303-1310.
42. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013; 369 ( 9): 840-851.
43. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA. 2009; 301 ( 23): 2445-2452.
44. Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specifi c adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother. 2011; 66 ( 5): 1110-1116.
45. Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy ( ' 3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: The prospective randomized Xtravent-study. Intensive Care Med. 2013; 39 ( 5): 847-856.
46. Calfee CS, Pugin J. The search for diagnostic markers in sepsis: many miles yet to go. Am J Respir Crit Care Med. 2012; 186 ( 1): 2-4.
47. Lascco announces a licensing agreement with Abbott for development and commercialization of pancreatic stone protein biomarker. Lajaunias Science Company website. http://www. lascco. com/News26-11-2012. html. Accessed May 10, 2015.